Steven Cohen Bicycle Therapeutics PLC Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 899,799 shares of BCYC stock, worth $18.3 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
899,799
Previous 58,500
1438.12%
Holding current value
$18.3 Million
Previous $1.18 Million
1623.56%
% of portfolio
0.06%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding BCYC
# of Institutions
112Shares Held
41.2MCall Options Held
39.6KPut Options Held
24.6K-
Baker Bros. Advisors LP New York, NY9.4MShares$191 Million2.28% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.55MShares$72.2 Million2.97% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.34MShares$47.6 Million9.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$45.9 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY1.96MShares$39.8 Million0.74% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $604M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...